Accentia Biopharmaceuticals, Inc.(fka ABPI)

[dix]

Going back to the first posts on this board I am reminded of how little and how much has changed since late 2007. BiovaxID is much closer to being available for treatment but the company still languishes in the morass of "one of hundreds of small biotech companies".

With the hurdles of bankruptcy and undercapitallization soon to be part of the historical record of ABPI/BVTI I expect management to put more effort into alerting the public to the potential of oncology vaccines, specifically as related to blood bourne cancers. The lack of awareness among oncology professionals and patients that I have met in the past few years is understandable given the day to day focus of most of these people. On the other hand I am slightly disconcerted that even with the success of Provenge most of those affected by cancer(s) have little or no appreciation for the potential treatment paradigm shift which looms in the near future.

Good fortune to us all,

Ten